CONSIDERATIONS TO KNOW ABOUT AZELAPRAG SMALL MOLECULE

The decision follows observations of liver transaminitis without the need of clinically substantial indications, and with out obvious dose dependence, in certain patients within the azelaprag arms on the STRIDES Stage 2 clinical trial for obesity (hyperlink).Apelin receptor agonists are now being pursued for their clinical inotropic potential from